Page 94 - The Flying Publisher Guide to Hepatitis C Treatment

94 | Hepatitis C Treatment

Hartwell D, Jones J, Baxter L, Shepherd J. Peginterferon alfa and ribavirin for
chronic hepatitis C in patients eligible for shortened treatment, re-
treatment or in HCV/HIV co-infection: a systematic review and economic
evaluation. Health Technol Assess 2011;15:1-210.
Hézode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or
without ribavirin for chronic HCV infection. N Engl J Med 2009;360:1839-50.
Iacob S, Cicinnati V, Hilgard P, et al. Predictors of graft and patient survival in
HCV recipients - model to predict HCV cirrhosis following liver
transplantation. Transplantation 2007;84:56-63.
Iacobellis A, Ippolito A, Andriulli A. Antiviral therapy in hepatitis C virus
cirrhotic patients in compensated and decompensated condition. World J
Gastroenterol 2008;14:6467-72.
Imbert-Bismut F, Ratziu V, Pieroni L,et al. Biochemical markers of liver fibrosis in
patients with hepatitis C virus infection: a prospective study. Lancet
2001;357:1069-75.
Iorio A, Marchesini E, Awad T, Gluud LL. Antiviral treatment for chronic hepatitis
C in patients with human immunodeficiency virus. Cochrane Database Syst
Rev 2010:CD004888.
Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic
hepatitis. J Hepatol 1995;22:696-9.
Jacobson I, Brown R, McCone J. Weight-based ribavirin dosing improves virologic
response in HCV-infected genotype 1 African Americans compared with
flat dose ribavirin with peginterferon alfa-2b combination therapy.
Hepatology 2004;40:217A.
Jamma S, Hussain G, Lau DT. Current Concepts of HBV/HCV coinfection:
coexistence, but not necessarily in harmony. Curr Hepat Rep 2010;9:260-9.
Jeffers LJ, Cassidy W, Howell CD, et al. Peginterferon alfa-2a (40kD) and ribavirin
for black American patients with chronic HCV genotype 1. Hepatology
2004;39:1702-8.
Jensen DM, Marcellin P, Freilich B, et al. Re-treatment of patients with chronic
hepatitis C who do not respond to peginterferon-alpha2b: a randomized
trial. Ann Intern Med 2009;150:528-40.
Kagawa T, Keeffe EB. Long-term effects of antiviral therapy in patients with
chronic hepatitis C. Hepat Res Treat 2010;2010:56278.
Kelleher TB, Mehta SH, Bhaskar R, et al. Prediction of hepatic fibrosis in
HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA
index. J Hepatol 2005;43:78–84.
Khattab MA, Eslam M, Sharwae MA, Shatat M, Ali A, Hamdy L. Insulin resistance
predicts rapid virologic response to peginterferon/ribavirin combination
therapy in hepatitis C genotype 4 patients. Am J Gastroenterol
2010;105:1970-7.
Kieffer TL, Kwong AD, Picchio GR. Viral resistance to specifically targeted
antiviral therapies for hepatitis C (STAT-Cs). J Antimicrob Chemother
2010;65:202-12.
Knott A, Dieperink E, Willenbring ML, et al. Integrated psychiatric/medical care
in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and
outcomes. Am J Gastroenterol 2006;101:2254-62.